Literature DB >> 21277289

Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2.

Toru Nishinaka1, Takeshi Miura, Manami Okumura, Fumika Nakao, Haruka Nakamura, Tomoyuki Terada.   

Abstract

Aldo-keto reductase 1B10 (AKR1B10) is an aldose reductase-like oxidoreductase of human origin. The expression of AKR1B10 is highly induced in the cells of various cancers such as lung non-small-cell carcinoma and hepatocellular carcinoma. Since the enzyme exhibits broad substrate specificities toward various xenobiotics such as anti-tumor drugs or various endogenous compounds such as retinaldehyde, AKR1B10 may play an important role in tumor progression or drug resistance. However, very little is known about its gene regulation. In this study, we investigated the regulation of AKR1B10 expression. A -3282bp of the 5'-flanking fragment of AKR1B10 gene was isolated from A549 lung carcinoma cells. This region contains several putative regulatory motifs such as AP-1, NF-κB and antioxidant response element. In addition, a complex polymorphic microsatellite with repetitive sequences enriched with C and T was found. However, luciferase reporter assay revealed that the microsatellite polymorphism did not influence the basal promoter activity. We found that an antioxidant ethoxyquin induced the AKR1B10 expression based on RT-PCR analysis and luciferase reporter assay. Since ethoxyquin is known to activate the gene expression mediated through transcription factor Nrf2, the involvement of Nrf2 was examined. Forced expression of dominant-negative Nrf2 mutant suppressed the ethoxyquin-induced AKR1B10 expression, and co-introduction of Nrf2 expression plasmid into the cells significantly augmented the luciferase reporter activity. Deletion analysis revealed that Nrf2-regulating cis-element(s) lay within -539bp of the 5'-flanking region. These results suggest that Nrf2 is one of the major factors involved in the AKR1B10 gene regulation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277289     DOI: 10.1016/j.cbi.2011.01.026

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  18 in total

1.  Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles.

Authors:  Abena S Agyeman; Raghothama Chaerkady; Patrick G Shaw; Nancy E Davidson; Kala Visvanathan; Akhilesh Pandey; Thomas W Kensler
Journal:  Breast Cancer Res Treat       Date:  2011-05-20       Impact factor: 4.872

2.  AKR1B10 accelerates the production of proinflammatory cytokines via the NF-κB signaling pathway in colon cancer.

Authors:  Cong Liu; Lei Shi; Wanyun Li; Zilan Huang; Shengyu Wang; Peilan Xu; Tingting Li; Zhenyu Li; Fanghong Luo; Wengang Li; Jianghua Yan; Ting Wu
Journal:  J Mol Histol       Date:  2022-08-03       Impact factor: 3.156

Review 3.  Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.

Authors:  Sreeparna Banerjee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Aldo-Keto Reductases 1B in Endocrinology and Metabolism.

Authors:  Emilie Pastel; Jean-Christophe Pointud; Fanny Volat; Antoine Martinez; Anne-Marie Lefrançois-Martinez
Journal:  Front Pharmacol       Date:  2012-08-02       Impact factor: 5.810

5.  Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.

Authors:  Shunsuke Sato; Takuya Genda; Katsuharu Hirano; Hironori Tsuzura; Yutaka Narita; Yoshio Kanemitsu; Tetsu Kikuchi; Katsuyori Iijima; Ryo Wada; Takafumi Ichida
Journal:  Liver Int       Date:  2012-06-11       Impact factor: 5.828

6.  Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.

Authors:  Toshiyuki Matsunaga; Yasuhiro Wada; Satoshi Endo; Midori Soda; Ossama El-Kabbani; Akira Hara
Journal:  Front Pharmacol       Date:  2012-01-31       Impact factor: 5.810

7.  Regulation of aldo-keto reductases in human diseases.

Authors:  Wei-Dong Chen; Yanqiao Zhang
Journal:  Front Pharmacol       Date:  2012-03-09       Impact factor: 5.810

8.  Propofol suppresses cell proliferation in gastric cancer cells through NRF2-mediated polyol pathway.

Authors:  Yajun Cao; Long Fan; Linkai Li; Jiexian Zhou
Journal:  Clin Exp Pharmacol Physiol       Date:  2021-11-09       Impact factor: 2.963

9.  Genetic variants in AKR1B10 associate with human eating behavior.

Authors:  Kerstin Rohde; Martin Federbusch; Annette Horstmann; Maria Keller; Arno Villringer; Michael Stumvoll; Anke Tönjes; Peter Kovacs; Yvonne Böttcher
Journal:  BMC Genet       Date:  2015-03-25       Impact factor: 2.797

Review 10.  The Role of AKR1B10 in Physiology and Pathophysiology.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Toru Nishinaka
Journal:  Metabolites       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.